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Background 
Herbal and dietary supplements (HDS) are being increasingly used for touted “health benefits” (1) and 
are responsible for over $36B in commerce in the US each year. (2,3) Broadly stated, HDS comprise 
single and multi-ingredient products that may include herbals, vitamins/minerals and amino acids. 
Hepatotoxicity  from HDS is increasingly being recognized. (4) In the US Drug Induced Liver Injury 
Network(DILIN) prospective study, products used as appearance and performance enhancing (APE) 
supplements are the most common subclass of HDS leading to liver injury.  Patients with hepatotoxicity 
from weight loss and other non-APE products can also sustain severe liver injury.  Despite these 
potential risks, HDS remain widely available in retail outlets and on the internet with little to no required 
safety or efficacy testing.   As a result, consumers are exposed to compounds whose biological effects 
are largely unknown in humans.  In addition, unlabeled ingredients added intentionally, accidentally, or 
as a byproduct of the manufacturing process comprise yet another risk of HDS to the consumer.  The 
HDS collected from DILIN enrollees were used to verify product labels and thus estimate the rate of label Au
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inaccuracy, as well as to search for known hepatotoxins and pharmaceuticals among HDS implicated in 
causing liver injury. 
Objective: 
The purpose of this study was to determine the veracity of the label on HDS consumed by patients 
enrolled into the DILIN, and to identify potential hepatotoxins in these products. 
Methods: 
The DILIN, a multicenter consortium funded by the National Institute for Diabetes and Digestive and 
Kidney Diseases, is studying the etiologies, risk factors, and outcomes of patients with drug induced liver 
injury (DILI).  All DILIN cases undergo a causality adjudication process that determines the likelihood of 
liver injury due to a drug or dietary supplement and implicates the product (drug or HDS) responsible.     
Between 2003 and 2015, the DILIN prospective study enrolled 341 HDS from 1268 patients with 
suspected DILI; 272 of these products had labels listing their ingredients and these underwent chemical 
analysis at the National Center for Natural Products Research of the University of Mississippi using ultra-
high-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometry 
(UHPLC-QToF-MS).  Of the 272, 96 products were directly implicated as a cause for liver injury in 71 
patients. 
The HDS products also were analyzed for known hepatotoxins, including aflatoxins, anabolic steroids, 
anthraquinones, pyrrolizidine alkaloids; and pharmaceuticals.  HDS were grouped per their marketed 
purpose for use, such as for APE or weight loss.  Mislabeling was defined as when the chemical analysis 
could not verify all ingredients listed on the label.  
Findings: 
Of the 272 products tested, only 132 had labels that accurately reflected the compounds identified by 
chemical analysis and thus 140 (51%)were mislabeled. These 140 products lacked at least one of the 
listed compounds (number of ingredients ranged from 1 to 21), and 55 products contained compounds 
not listed on the label, including 2 that were pharmaceuticals.  The overall mislabeling rate was 51% and 
rates were higher for steroidal (82%) than botanical (44%) and vitamin (49%) products.  When 
categorized by marketed purpose of the HDS, the rates of mislabeling were highest for sexual 
enhancers, APE, and weight loss products (Table).  Adulterants found in the 91 products with known 
hepatotoxins included anabolic steroids in 13 of 26 products; diclofenac in an agent for arthritis; and 
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tamoxifen in a bodybuilding product.  In the two latter cases, the clinical features of liver injury were 
consistent with the adulterants’ reported biochemical and clinical liver injury pattern.    
 
Discussion: 
We identified an alarmingly high rate of mislabeling in HDS collected from patients enrolled into the 
DILIN study.  Products used for APE and weight loss had the highest rates of mislabeling.  In the two 
cases of pharmaceutical adulteration, the clinical features were highly consistent with that reported due 
to the identified adulterants. (5)   
Our findings highlight that a large proportion of commercially available HDS are mislabeled, exposing 
consumers to substances unknowingly, some of which may be responsible for liver injury.  At this time, 
we are unable to determine which of the compounds or combination of compounds are responsible for 
the observed liver injury. Nonetheless, the high rate of mislabeling including identification of agents 
recognized to cause liver injury may expose consumers to unrecognized risk including interactions with 
prescribed medications. These preliminary findings suggest that more stringent regulation of HDS is 
required to improve the accuracy and to verify product labels to avoid potential adverse health events 
including liver injury. 
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Table: Mislabeling in HDS collected by the DILIN 
 Category HDS with 
Labels  
Mislabeled HDS (%)  
General Health 53 26   (49%) 
Appearance & 
Performance 
Enhancing 
46 37   (80%) 
Weight Loss 36 26   (72%) 
GI Symptoms 22   9   (41%) 
Energy Boosters 5  3   (60%) 
Sexual Enhancers 4   4   (100%) 
Misc or Unknown 106 35  (33%) 
TOTAL 272 140 (51%) 
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